ATRA
insider transactionsAtara Biotherapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+100.7K
507.4K buy · 406.8K sell
Net value · 365d
$994.4K
$4.7M in · $3.7M out
Sentiment · 365d
Net buying
56% buying · 44% selling
Open-market trades · 365d
13
507.4K buy · 406.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
24.0K sh
Own +63%
-
Grant·A
Director
$0
12.0K sh
Own +54%
-
Grant·A
Director
$0
12.0K sh
Own +66%
-
Grant·A
Director, 10% Owner
$0
12.0K sh
Own New
-
Sell·S
Anhco Nguyen KEY
President and CEO
$47.8K
5.2K sh · $9.13
Own -4%
-
Sell·S
Chief Accounting Officer
$22.0K
2.4K sh · $9.13
Own -5%
-
Sell·S
Panacea Innovation Ltd / James Huang
10% Owner
$3.2M
313.4K sh · $10.10
Own -24%
-
Buy·P
10% Owner
$4.7M
507.4K sh · $9.35
Own +49%
-
Exercise·M
Panacea Innovation Ltd / James Huang
10% Owner
$1.7M
259.2K sh · $6.61
Own New
-
Other·F
Panacea Innovation Ltd / James Huang
10% Owner
$26
5 sh · $5.23
Own -0%
-
Exercise·M
Panacea Innovation Ltd / James Huang
10% Owner
$26
259.2K sh · $0.00
Own +532%
-
Grant·A
Anhco Nguyen KEY
President and CEO
$0
81.1K sh
Own +131%
-
Grant·A
Chief Accounting Officer
$0
20.3K sh
Own +64%
-
Sell·S
Chief Accounting Officer
$508
100 sh · $5.08
Own -0%
-
Sell·S
Chief Accounting Officer
$1.9K
377 sh · $5.08
Own -1%
-
Sell·S
Chief Accounting Officer
$8.1K
1.6K sh · $5.08
Own -5%
-
Sell·S
Chief Accounting Officer
$122
24 sh · $5.08
Own -0%
-
Sell·S
Anhco Nguyen KEY
President and CEO
$7.3K
1.4K sh · $5.09
Own -2%
-
Sell·S
Anhco Nguyen KEY
President and CEO
$6.6K
1.3K sh · $5.09
Own -2%
-
Sell·S
Anhco Nguyen KEY
President and CEO
$295
58 sh · $5.08
Own -0%
-
Sell·S
Anhco Nguyen KEY
President and CEO
$1.0K
198 sh · $5.08
Own -0%
-
Sell·S
Panacea Innovation Ltd / James Huang
10% Owner
$489.0K
80.6K sh · $6.07
Own -6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Brian N Cherry | Grant A | 24.0K | $0 |
| Jun 9, 2026 | William K Heiden | Grant A | 12.0K | $0 |
| Jun 9, 2026 | Matthew K Fust | Grant A | 12.0K | $0 |
| Jun 9, 2026 | Gregory Austin Ciongoli | Grant A | 12.0K | $0 |
| May 18, 2026 | Anhco Nguyen KEY | Sell S | 5.2K | $47.8K |
| May 18, 2026 | Yanina Grant-Huerta | Sell S | 2.4K | $22.0K |
| May 7, 2026 | Panacea Innovation Ltd / James Huang | Sell S | 313.4K | $3.2M |
| May 7, 2026 | EcoR1 Capital, LLC | Buy P | 507.4K | $4.7M |
| Mar 17, 2026 | Panacea Innovation Ltd / James Huang | Exercise M | 259.2K | $1.7M |
| Mar 17, 2026 | Panacea Innovation Ltd / James Huang | Other F | 5 | $26 |
| Mar 17, 2026 | Panacea Innovation Ltd / James Huang | Exercise M | 259.2K | $26 |
| Mar 9, 2026 | Anhco Nguyen KEY | Grant A | 81.1K | $0 |
| Mar 9, 2026 | Yanina Grant-Huerta | Grant A | 20.3K | $0 |
| Mar 2, 2026 | Yanina Grant-Huerta | Sell S | 100 | $508 |
| Mar 2, 2026 | Yanina Grant-Huerta | Sell S | 377 | $1.9K |
| Mar 2, 2026 | Yanina Grant-Huerta | Sell S | 1.6K | $8.1K |
| Mar 2, 2026 | Yanina Grant-Huerta | Sell S | 24 | $122 |
| Mar 2, 2026 | Anhco Nguyen KEY | Sell S | 1.4K | $7.3K |
| Mar 2, 2026 | Anhco Nguyen KEY | Sell S | 1.3K | $6.6K |
| Mar 2, 2026 | Anhco Nguyen KEY | Sell S | 58 | $295 |
| Mar 2, 2026 | Anhco Nguyen KEY | Sell S | 198 | $1.0K |
| Jan 12, 2026 | Panacea Innovation Ltd / James Huang | Sell S | 80.6K | $489.0K |
About ATRA insider trading
This page tracks insider transactions for Atara Biotherapeutics, Inc. (ATRA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.